Literature DB >> 23576730

Temporal association of elevated cholecystokininergic tone and adolescent trauma is critical for posttraumatic stress disorder-like behavior in adult mice.

Anu Joseph1, Mingxi Tang, Takayoshi Mamiya, Qian Chen, Ling-Ling Yang, Jianwei Jiao, Na Yu, Ya-Ping Tang.   

Abstract

Adolescent trauma (AT) is a common risk factor for adult-onset posttraumatic stress disorder (PTSD). However, the vulnerability to AT among different individuals varies dramatically, indicating that other cofactors are important. Despite extensive studies, the identification of those cofactors has had little success. Here, we found that after subjected to traumatic stress at postnatal day 25 (P25), a stage that is comparable to the human adolescent period, inducible/reversible forebrain-specific cholecystokinin receptor-2 transgenic (IF-CCKR-2 tg) mice exhibited a significantly higher level of PTSD-like behavior at a later life (adult) stage compared with their wild-type littermates. Moreover, in these traumatized IF-CCKR-2 tg mice, both the glucocorticoid negative feedback inhibition and spatial learning and memory were impaired. Interestingly, if the CCKR-2 transgene was specifically suppressed during the time of AT exposure, these observations were largely diminished, indicating that a temporal association of the elevated CCKergic tone and AT is pathogenically critical. Treatment of traumatized IF-CCKR-2 tg mice with fluoxetine, a selective serotonin reuptake inhibitor, for a period of 4 wk significantly attenuated the PTSD-like behavior and the impaired glucocorticoid negative feedback inhibition, but not the memory deficit, implying that the memory deficit is an independent post-AT clinical entity and not a consequence of PTSD. Taken together, these results reveal a dynamic role of the CCKergic system in the development of post-AT psychopathologies and suggest that a timely antagonism of CCKR-2 activity during AT exposure is a potential preventive strategy for post-AT psychopathologies including PTSD and cognitive dysfunction.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23576730      PMCID: PMC3631685          DOI: 10.1073/pnas.1219601110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

Review 1.  Cholecystokinin modulation of mesolimbic dopamine function: regulation of motivated behaviour.

Authors:  Susan Rotzinger; David E A Bush; Franco J Vaccarino
Journal:  Pharmacol Toxicol       Date:  2002-12

2.  Immunochemical evidence of cholecystokinin-like peptides in brain.

Authors:  G J Dockray
Journal:  Nature       Date:  1976-12-09       Impact factor: 49.962

3.  Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study.

Authors:  P Zwanzger; D Eser; S Aicher; C Schüle; T C Baghai; F Padberg; R Ella; H-J Möller; R Rupprecht
Journal:  Neuropsychopharmacology       Date:  2003-03-26       Impact factor: 7.853

4.  Behavioral and endocrine response to cholecystokinin tetrapeptide in patients with posttraumatic stress disorder.

Authors:  M Kellner; K Wiedemann; A Yassouridis; R Levengood; L S Guo; F Holsboer; R Yehuda
Journal:  Biol Psychiatry       Date:  2000-01-15       Impact factor: 13.382

5.  The prevalence of potentially traumatic events in childhood and adolescence.

Authors:  E Jane Costello; Alaattin Erkanli; John A Fairbank; Adrian Angold
Journal:  J Trauma Stress       Date:  2002-04

6.  Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurones.

Authors:  J Bradwejn; C de Montigny
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

Review 7.  SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations.

Authors:  Gregory M Asnis; Shari R Kohn; Margaret Henderson; Nicole L Brown
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Prevalence of civilian trauma and posttraumatic stress disorder in a representative national sample of women.

Authors:  H S Resnick; D G Kilpatrick; B S Dansky; B E Saunders; C L Best
Journal:  J Consult Clin Psychol       Date:  1993-12

9.  Neurobiological basis of failure to recall extinction memory in posttraumatic stress disorder.

Authors:  Mohammed R Milad; Roger K Pitman; Cameron B Ellis; Andrea L Gold; Lisa M Shin; Natasha B Lasko; Mohamed A Zeidan; Kathryn Handwerger; Scott P Orr; Scott L Rauch
Journal:  Biol Psychiatry       Date:  2009-09-12       Impact factor: 13.382

10.  Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers.

Authors:  Peter Zwanzger; Daniela Eser; Frank Padberg; Thomas C Baghai; Cornelius Schule; Florian Rötzer; Robin Ella; Hans-Jürgen Möller; Rainer Rupprecht
Journal:  Depress Anxiety       Date:  2003       Impact factor: 6.505

View more
  5 in total

1.  Effects of paroxetine on PTSD-like symptoms in mice.

Authors:  Yassine Bentefour; Mohamed Bennis; René Garcia; Saadia Ba M'hamed
Journal:  Psychopharmacology (Berl)       Date:  2015-01-15       Impact factor: 4.530

2.  The entorhinal cortex modulates trace fear memory formation and neuroplasticity in the mouse lateral amygdala via cholecystokinin.

Authors:  Hemin Feng; Junfeng Su; Wei Fang; Xi Chen; Jufang He
Journal:  Elife       Date:  2021-11-15       Impact factor: 8.140

3.  Interaction between the cholecystokinin and endogenous cannabinoid systems in cued fear expression and extinction retention.

Authors:  Mallory E Bowers; Kerry J Ressler
Journal:  Neuropsychopharmacology       Date:  2014-09-01       Impact factor: 7.853

4.  The 5-HT3A receptor is essential for fear extinction.

Authors:  Makoto Kondo; Yukiko Nakamura; Yusuke Ishida; Takahiro Yamada; Shoichi Shimada
Journal:  Learn Mem       Date:  2013-12-16       Impact factor: 2.460

5.  Therapeutic Action of Fluoxetine is Associated with a Reduction in Prefrontal Cortical miR-1971 Expression Levels in a Mouse Model of Posttraumatic Stress Disorder.

Authors:  Ulrike Schmidt; Leonie Herrmann; Kathrin Hagl; Bozidar Novak; Christine Huber; Florian Holsboer; Carsten T Wotjak; Dominik R Buell
Journal:  Front Psychiatry       Date:  2013-07-10       Impact factor: 4.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.